- Home
- STTK vs EARN Comparison
STTK vs EARN Comparison
Compare STTK & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- EARN
- Stock Information
- Founded
- STTK 2016
- EARN 2012
- Country
- STTK United States
- EARN United States
- Employees
- STTK N/A
- EARN N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- STTK Health Care
- EARN Real Estate
- Exchange
- STTK Nasdaq
- EARN Nasdaq
- Market Cap
- STTK 56.8M
- EARN 187.6M
- IPO Year
- STTK 2020
- EARN 2013
- Fundamental
- Price
- STTK $1.12
- EARN $6.48
- Analyst Decision
- STTK Hold
- EARN Hold
- Analyst Count
- STTK 3
- EARN 1
- Target Price
- STTK $2.00
- EARN N/A
- AVG Volume (30 Days)
- STTK 182.2K
- EARN 524.2K
- Earning Date
- STTK 02-27-2025
- EARN 03-05-2025
- Dividend Yield
- STTK N/A
- EARN 14.79%
- EPS Growth
- STTK N/A
- EARN 277.67
- EPS
- STTK N/A
- EARN 1.02
- Revenue
- STTK $6,435,000.00
- EARN N/A
- Revenue This Year
- STTK $313.04
- EARN N/A
- Revenue Next Year
- STTK N/A
- EARN $89.08
- P/E Ratio
- STTK N/A
- EARN $6.33
- Revenue Growth
- STTK 382.75
- EARN N/A
- 52 Week Low
- STTK $0.94
- EARN $5.54
- 52 Week High
- STTK $11.76
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- EARN 42.60
- Support Level
- STTK $1.13
- EARN $6.30
- Resistance Level
- STTK $1.39
- EARN $6.68
- Average True Range (ATR)
- STTK 0.11
- EARN 0.13
- MACD
- STTK 0.00
- EARN -0.02
- Stochastic Oscillator
- STTK 18.18
- EARN 32.14
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.